[go: up one dir, main page]

SG11201910085UA - Atropine pharmaceutical compositions - Google Patents

Atropine pharmaceutical compositions

Info

Publication number
SG11201910085UA
SG11201910085UA SG11201910085UA SG11201910085UA SG 11201910085U A SG11201910085U A SG 11201910085UA SG 11201910085U A SG11201910085U A SG 11201910085UA SG 11201910085U A SG11201910085U A SG 11201910085UA
Authority
SG
Singapore
Prior art keywords
new jersey
international
atropine
pct
road
Prior art date
Application number
Inventor
Navneet Puri
Prem Sagar Akasapu
Irfan A Mohammed
Kumaresh Soppimath
Iouri V Ilitchev
Tao Zhang
Original Assignee
Nevakar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64096170&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201910085U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nevakar Inc filed Critical Nevakar Inc
Publication of SG11201910085UA publication Critical patent/SG11201910085UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

WO 18/ 20905 1 Al Tronskr Met.Tarrir le . Cr. POIrrwerSoutom.81,rank Figure 1 coop= ny lra, lor 1.tridlon drrArtxne. cool Gowns, 20-25 . C. CM1clotc Artrual pri Mr, 1.10rachloric um Mydroxice5olar6, =rho: IrdErtssrreinp PARlIGULATE PEOLICnON FILTPAIION irn.rj rminlararre r• r ertle Vor 6aIritiaro Stale Bulk Formulation of Arimpeullato lne.Madan nbnt• rat Ire than 60 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 15 November 2018 (15.11.2018) WIPO I PCT ~ill IIIIIIIIII1101DIVIIIIIIIHo o Holoiloimollmuoinio oimIE (10) International Publication Number WO 2018/209051 Al (51) International Patent Classification: A61K 9/00 (2006.01) A61K 47/18 (2006.01) A61K 9/08 (2006.01) A61K 31/46 (2006.01) A61K 47/38 (2006.01) A61P 27/02 (2006.01) (21) International Application Number: PCT/US2018/032017 (22) International Filing Date: 10 May 2018 (10.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/505,027 11 May 2017 (11.05.2017) US (71) Applicant: NEVAKAR INC. [US/US]; 1019 Route 202/206, Bldg. K, Bridgewater, New Jersey 08807 (US). (72) Inventors: PURI, Navneet; 40 Still Hollow Road, Lebanon, New Jersey 08833 (US). AKASAPU, Prem Sa- gar; 906 Rivendell Way, Edison, New Jersey 08817 (US). MOHAMMED, Irfan A.; 1900 Frontage Road, Apt. 1113, Cherry Hill, New Jersey 08034 (US). SOPPIMATH, Ku- maresh; 97 Autumn Lane, Skillman, New Jersey 08558 (US). ILITCHEV, bowl V.; 21 Reed Road, Hillsborough, New Jersey 08844 (US). ZHANG, Tao; 52 Douglas Drive, Towaco, New Jersey 07082 (US). (74) Agent: FESSENMAIER, Martin; Umberg Zipser LLP, 1920 Main Street, Suite 750, Irvine, California 92614 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: ATROPINE PHARMACEUTICAL COMPOSITIONS (57) : The inventive subject matter is directed to composi- tions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compo- sitions presented herein are substantially preservative free and ex- hibit less than 0.35% tropic acid from degradation of atropine. Ad- vantageously, contemplated formulations are also substantially free of preservatives. [Continued on next page] WO 2018/209051 Al MIDEDIM01101DEIRDEIO10010101101MOIREM01111110110111111 Published: — with international search report (Art. 21(3)) with amended claims (Art. 19(1))
SG11201910085U 2017-05-11 2018-05-10 Atropine pharmaceutical compositions SG11201910085UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762505027P 2017-05-11 2017-05-11
PCT/US2018/032017 WO2018209051A1 (en) 2017-05-11 2018-05-10 Atropine pharmaceutical compositions

Publications (1)

Publication Number Publication Date
SG11201910085UA true SG11201910085UA (en) 2019-11-28

Family

ID=64096170

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201910085U SG11201910085UA (en) 2017-05-11 2018-05-10 Atropine pharmaceutical compositions

Country Status (23)

Country Link
US (14) US10251875B2 (en)
EP (2) EP3970694A1 (en)
JP (5) JP6557379B2 (en)
KR (1) KR102281667B1 (en)
CN (1) CN110621298B (en)
AU (1) AU2018265257B2 (en)
CA (1) CA3063228C (en)
CL (1) CL2019003228A1 (en)
CO (1) CO2019012893A2 (en)
CY (1) CY1124880T1 (en)
ES (1) ES2901140T3 (en)
HR (1) HRP20212019T1 (en)
HU (1) HUE056595T2 (en)
LT (1) LT3548000T (en)
MX (1) MX2019013218A (en)
PH (1) PH12019502701A1 (en)
PL (1) PL3548000T3 (en)
PT (1) PT3548000T (en)
RS (1) RS62817B1 (en)
RU (1) RU2745603C1 (en)
SG (1) SG11201910085UA (en)
SI (1) SI3548000T1 (en)
WO (1) WO2018209051A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
JP2018521000A (en) 2015-05-29 2018-08-02 シドネキシス，インク． Pharmaceutical formulation stabilized with D2O
CN117205210A (en) * 2016-05-25 2023-12-12 新加坡保健服务集团 Atropine-containing aqueous composition
SG11201910085UA (en) * 2017-05-11 2019-11-28 Nevakar Inc Atropine pharmaceutical compositions
CN111093742B (en) 2017-06-10 2022-09-16 艾诺维亚股份有限公司 Method and apparatus for handling and delivering fluid to the eye
US11554115B2 (en) * 2018-03-14 2023-01-17 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative for treatment of triple-negative breast cancer
JP7378959B2 (en) * 2018-05-11 2023-11-14 千寿製薬株式会社 Ophthalmic composition
CN114533652B (en) * 2018-09-25 2024-12-13 沈阳兴齐眼药股份有限公司 Pharmaceutical composition, preparation method and use thereof
WO2020219707A1 (en) * 2019-04-24 2020-10-29 Allergan, Inc. Compositions and methods for treatment of ocular conditions
WO2021001806A1 (en) * 2019-07-04 2021-01-07 Ocular Discovery Ltd. Stable dipyridamole formulations with reduced impurities
EP4072483A4 (en) 2019-12-11 2024-02-07 Eyenovia, Inc. Systems and devices for delivering fluids to the eye and methods of use
AU2020404934A1 (en) * 2019-12-16 2022-07-07 Sydnexis, Inc. Ophthalmic compositions comprising D2O
CN110917133A (en) * 2019-12-23 2020-03-27 河北科技大学 A kind of eye drops for treating myopia and preparation method thereof
WO2021226153A1 (en) * 2020-05-05 2021-11-11 The Procter & Gamble Company Oral care compositions comprising dicarboxylic acid
CN111821259A (en) * 2020-07-14 2020-10-27 艾尔健康眼药(辽宁)有限公司 Medicinal composition for eyes
CN111840221A (en) * 2020-08-25 2020-10-30 安徽博诺美科生物医药有限公司 Atropine sulfate eye drops
WO2022130033A1 (en) * 2020-12-17 2022-06-23 Sun Pharmaceutical Industries Limited An aqueous sterile solution of atropine for ophthalmic use
CA3211874A1 (en) * 2021-03-16 2022-09-22 Kumaresh Soppimath Multi-dose container for ophthalmic compositions
EP4088714A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
EP4088713A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
CN113440486B (en) * 2021-06-02 2022-12-20 苏州欧康维视生物科技有限公司 An eye drop composition for preventing or treating ophthalmic diseases, and its preparation method
WO2023086878A1 (en) * 2021-11-10 2023-05-19 Visus Therapeutics, Inc. Carbachol formulations to enhance anti-presbyopia effects
CN114129511A (en) * 2021-12-07 2022-03-04 河南润弘制药股份有限公司 Atropine sulfate injection with improved stability
WO2023152642A1 (en) * 2022-02-08 2023-08-17 Avaca Pharma Private Limited Ophthalmic compositions and methods thereof
US20230277521A1 (en) * 2022-03-07 2023-09-07 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions
CN114569551A (en) * 2022-03-21 2022-06-03 杭州赫尔斯科技有限公司 Atropine eye drops and preparation method thereof
WO2023201315A2 (en) * 2022-04-14 2023-10-19 TearClear Corp. Ophthalmic agent in preservative removal device
CN115177584A (en) * 2022-07-14 2022-10-14 成都市海通药业有限公司 Preparation method of atropine sulfate injection
WO2024091789A1 (en) * 2022-10-26 2024-05-02 Vyluma Inc. Childhood atropine for myopia progression
CN115998692A (en) * 2023-02-15 2023-04-25 苏州欧康维视生物科技有限公司 Atropine drug product and application thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU86521A1 (en) 1986-07-18 1988-02-02 Oreal HAIR DYEING PROCESS WITH HYDROXYQUINONIC DYES AND METAL SALTS
IL85312A (en) 1988-02-03 1991-08-16 Israel State Injectable pharmaceutical compositions having improved stability
JP2617508B2 (en) 1988-02-05 1997-06-04 エーザイ株式会社 Stable aqueous solution containing diphenhydramine
US5460834A (en) * 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
US5716952A (en) * 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
SE9401108D0 (en) * 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
US20030129083A1 (en) 1997-11-26 2003-07-10 Advanced Medical Optics, Inc. Multi purpose contact lens care compositions including propylene glycol or glycerin
US6164282A (en) 1999-01-27 2000-12-26 Allergan Sales, Inc. Methods for restoring and/or enhancing accommodation in pseudo phakia
ES2392636T3 (en) * 2000-07-14 2012-12-12 Allergan, Inc. Compositions containing therapeutically active components that have improved solubility
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
CN101049287A (en) 2006-04-07 2007-10-10 财团法人长庚纪念医院 Low-concentration atropine ophthalmic agent for inhibiting myopia increase and its manufacturing method
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
JP2007308398A (en) * 2006-05-17 2007-11-29 Chang Gung Memorial Hospital Eye drops and manufacturing method thereof
EA019867B1 (en) * 2007-10-08 2014-06-30 Фовея Фармасьютикалс Aqueous ophthalmic formulations
WO2010083129A2 (en) 2009-01-13 2010-07-22 The Regents Of The University Of California Implantable delivery vehicle for ocular delivery of muscarinic antagonists
US20120203161A1 (en) 2009-08-12 2012-08-09 Seros Medical, Llc Deuterated water and riboflavin solution for extending singlet oxygen lifetimes in treatment of ocular tissue and method of use
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
JP5753957B2 (en) * 2013-01-31 2015-07-22 千寿製薬株式会社 Stable aqueous solution
CA3050457C (en) 2013-05-06 2021-05-25 Kaohsiung Chang Gung Memorial Hospital A pharmaceutical composition comprising atropine and nsaid for treating myopia
WO2015055301A1 (en) * 2013-10-15 2015-04-23 Pharmathen S.A. Preservative free pharmaceutical compositions for ophthalmic administration
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US20160009705A1 (en) * 2014-06-24 2016-01-14 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
WO2016013993A1 (en) 2014-07-25 2016-01-28 Imuneks Farma Llac Sanayi Ve Ticaret A.Ş. Stable preservative free ophthalmic formulations of opioid antagonists
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
CN107920984A (en) * 2015-06-18 2018-04-17 远视眼治疗有限责任公司 The composition of stable storing and the not positive method for the treatment of ophthalmic refractive
CN117205210A (en) 2016-05-25 2023-12-12 新加坡保健服务集团 Atropine-containing aqueous composition
SG11201910085UA (en) 2017-05-11 2019-11-28 Nevakar Inc Atropine pharmaceutical compositions
US11191751B1 (en) 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions

Also Published As

Publication number Publication date
US12036217B2 (en) 2024-07-16
EP3970694A1 (en) 2022-03-23
US11730728B2 (en) 2023-08-22
SI3548000T1 (en) 2022-02-28
BR112019023515A2 (en) 2020-05-19
CY1124880T1 (en) 2022-11-25
US20190183876A1 (en) 2019-06-20
NZ758555A (en) 2021-10-29
CL2019003228A1 (en) 2020-01-31
US10583132B2 (en) 2020-03-10
US10568875B2 (en) 2020-02-25
CA3063228A1 (en) 2018-11-15
USRE50040E1 (en) 2024-07-16
PT3548000T (en) 2021-12-10
US10610525B2 (en) 2020-04-07
JP6557379B2 (en) 2019-08-07
EP3548000A4 (en) 2019-12-04
US20230355604A1 (en) 2023-11-09
WO2018209051A1 (en) 2018-11-15
CN110621298A (en) 2019-12-27
US11642338B2 (en) 2023-05-09
KR20190138714A (en) 2019-12-13
JP7332179B2 (en) 2023-08-23
PL3548000T3 (en) 2022-01-17
EP3548000A1 (en) 2019-10-09
HUE056595T2 (en) 2022-02-28
JP2021102647A (en) 2021-07-15
US11707458B2 (en) 2023-07-25
MX2019013218A (en) 2022-05-24
US20190192499A1 (en) 2019-06-27
KR102281667B9 (en) 2024-01-08
PH12019502701A1 (en) 2020-12-07
CO2019012893A2 (en) 2020-02-28
JP6681503B2 (en) 2020-04-15
LT3548000T (en) 2022-03-10
CN110621298B (en) 2022-12-20
US20240342154A1 (en) 2024-10-17
RU2745603C1 (en) 2021-03-29
US11730727B2 (en) 2023-08-22
JP2019172704A (en) 2019-10-10
AU2018265257B2 (en) 2020-08-06
JP6865476B2 (en) 2021-04-28
AU2018265257A1 (en) 2019-11-14
RS62817B1 (en) 2022-02-28
US11464769B2 (en) 2022-10-11
US10251875B2 (en) 2019-04-09
US20200352928A1 (en) 2020-11-12
US20190209545A1 (en) 2019-07-11
US20200405705A1 (en) 2020-12-31
JP2019172705A (en) 2019-10-10
US20200397776A1 (en) 2020-12-24
US20190175580A1 (en) 2019-06-13
US20210128546A1 (en) 2021-05-06
JP2018188440A (en) 2018-11-29
JP6681502B2 (en) 2020-04-15
US20180325888A1 (en) 2018-11-15
US11071732B2 (en) 2021-07-27
EP3548000B1 (en) 2021-11-10
ES2901140T3 (en) 2022-03-21
US20190175579A1 (en) 2019-06-13
US10576074B2 (en) 2020-03-03
US20200397775A1 (en) 2020-12-24
JP2019194248A (en) 2019-11-07
CA3063228C (en) 2022-06-28
KR102281667B1 (en) 2021-07-23
HRP20212019T1 (en) 2022-04-01

Similar Documents

Publication Publication Date Title
SG11201910085UA (en) Atropine pharmaceutical compositions
SG11201908540PA (en) Stable antibody formulation
SG11201808799SA (en) Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201810161RA (en) Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201804811WA (en) Fenfluramine compositions and methods of preparing the same
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201809534UA (en) Methods of treating autoimmune disease using allogeneic t cells
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201809853PA (en) Multi-material wires for additive manufacturing of titanium alloys
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201906164RA (en) Bicyclic inhibitors of histone deacetylase
SG11201909825VA (en) Hsp90 inhibitor oral formulations and related methods
SG11201807023QA (en) Compositions and methods for preventing and/or treating vitamin b12 deficiency